TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Bolus)
Description: SC in the upper arm
Study: NCT04170426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study: NCT05880654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling & root planning
Description: Non Surgical periodontal therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling & root planning
Description: Non Surgical periodontal therapy
Study: NCT06216483

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PDM Alert
Description: passive digital marker (PDM) for postoperative delirium risk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDM Alert
Description: passive digital marker (PDM) for postoperative delirium risk
Study: NCT06453447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (cellulose) PO once daily for 14 days starting day of surgery
Study: NCT05624554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study: NCT04170426

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study: NCT05624554

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Truxima
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study: NCT06275412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The 3Ms 2.0 Intervention
Description: The 3Ms is a culturally tailored, mHealth intervention for primary caregivers of Black adolescents with T1D focused on promoting daily parental monitoring of adolescent diabetes care and delivered via an Internet platform, Computer Intervention Authoring System (CIAS). The intervention content is based on the Information-Motivation-Behavioral Skills (IMB) model. Caregivers randomized to The 3Ms receive 3 sessions. The caregiver is guided through each session by an interactive and emotive three-dimensional narrator that reads and speaks aloud. Additional intervention content includes brief videoclips to provide skills demonstrations of supportive parenting practices related to diabetes care and text message reminders. Each session is no more than 20 minutes in length. The intervention is delivered over a three-month window, with the two follow-up sessions available to be accessed by the caregiver at one-month intervals after completion of the initial session.
Study: NCT05624554

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ruxience
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Riabni
Description: Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Study: NCT06275412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Attention Control (EAC)
Description: The EAC intervention consists of three sessions delivered in an mHealth format via the CIAS internet platform over three months, with access for a maximum of six months. EAC provides structured information on topics of interest to caregivers of adolescents with T1D such as travelling with diabetes, or emergency preparedness for persons with diabetes. All participants receive their standard medical care.
Study: NCT05367336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: second group will be receiving morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: third group receiving fentanyl
Study: NCT06080425

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Medical Nutrition Therapy
Description: Counselling
Study: NCT05014828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Capsules administered orally
Study: NCT05915923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 Hz Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 1Hz)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 Hz Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received rTMS once a day (stimulation plan: stimulation of M1 region on the dominant hemisphere at 10Hz)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: After enrollment, healthy adults received sham-rTMS once a day with the same parameters as the 10 Hz rTMS group, but the coil rotated 90° away from the scalp
Study: NCT06106152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX212A injection
Description: The WTX212A infusion is given every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX212A injection
Description: The WTX212A infusion is given every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD -1/PD-L1 monoclonal antibody
Description: The PD -1/PD-L1 monoclonal antibody is given every 21 days
Study: NCT06033209

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Fractioned)
Description: SC in the upper arm, Fractionated escalating dose for prime

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMNP (SC, Fractioned)
Description: SC in the upper arm, Fractionated escalating dose for prime
Study: NCT06076213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets
Study: NCT05014828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: intravenous (iv) infusion
Study: NCT06422208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous midbrain dopamine neurons
Description: The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.
Study: NCT06241014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization and Sling Exercises
Description: Mulligan mobilizations along with sling exercises. Mulligan mobilizations include SNAGs. Participants will receive 3 sets of mulligan mobilization techniques per session, each set involving 10 times repetition of the exercise. The interval between the sets will be 15 to 20 seconds. The technique will be repeated total of six times having two sessions per week for 3 weeks. For the sling exercise, the sling exercise program will also be applied for 3 weeks, 2 times a week for 20 minutes per day. To perform the exercise, the subjects will be instructed with a demonstration and explanation.
Study: NCT05992324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caption LungAI
Description: Caption LungAI is a software that is designed to help non-expert healthcare professionals acquire diagnostic quality images on an 8-zone lung protocol for both healthy patients and patients presenting with pathology such as B-Lines.
Study: NCT04950166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegsitacianine
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Study: NCT02747303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
Study: NCT05798611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Randomized patients will orally receive ART0380.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART0380
Description: Randomized patients will orally receive ART0380.
Study: NCT06036914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Bumetanide will be administered via intravenous (IV) infusion at a dose of 12.5 mg two times a day (BID) for 2 doses total within 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide will be administered via intravenous (IV) infusion at usual doses (twice the home dose of oral daily diuretic in furosemide equivalents) administered as 2 doses total within 24 hours.~Furosemide equivalents will be considered as follows (40 mg of intravenous furosemide = 1 mg oral bumetanide or 40 mg of torsemide or 80 mg of oral furosemide consistent with prior literature). The lowest dose of furosemide administered during the study will be 40 mg IV two times a day (BID) and the maximum dose will be 100 mg IV BID.
Study: NCT05060887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836-003
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836-003
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836-003
Description: One single administration intramuscularly at Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: One single administration intramuscularly at Day 1.
Study: NCT05146973

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-TLX591
Description: TLX591, a monoclonal antibody conjugated with a DOTA chelator and radiolabelled with 177Lu (177Lu-DOTA-TLX591)
Study: NCT06004882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNS therapy
Description: PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNS therapy
Description: PNS therapy-NS is a 60-day therapy targeting chronic pain. The procedure involves implanting a small piece of wire next to the nerve causing pain, and the wire is connected to an external device that is then used to apply electric pulses to the nerve, blocking pain signals, for 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Given by Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Given by Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given by Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given by Injection
Study: NCT06241014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Mobilization
Description: Mulligan Mobilization
Study: NCT06559540

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated radiation
Description: External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes,

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-hypofractionated breast/chest wall and regional nodal radiation
Description: External beam photon therapy with IMRT or VMAT to the breast/chestwall and regional lymph nodes, including supraclavicular, infraclavicular, axillary, and internal mammary nodes
Study: NCT06004882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given by Injection
Study: NCT05926739

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrical stimulation and biofeedback with Phenix Liberty medical device
Description: 12 sessions of electrical stimulation and biofeedback performed between 6 and 8 weeks at regular intervals according to a schedule drawn up by the physiotherapist.~The patient will undergo 12 therapeutic functional reeducation sessions, at regular intervals according to a schedule drawn up by the physiotherapist, during which the PHENIX LIBERTY device may be used. The patients will complete questionnaires at the end of the care.~Overall, the functional rehabilitation sessions will include muscle testing, electrostimulation and biofeedback.~The follow up will be conduct as follow :~* 12 sessions between 6 and 8 weeks~* 1 end visit, within the week after the 12th session
Study: NCT04170426

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous adipose derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Study: NCT04162171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT) ablation of VT
Description: Additional imaging for SBRT planning and implementation:~* Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~* SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems.
Study: NCT06428305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Providing hygiene education based on the method of teaching what has been learned in the context of a genital hygiene guide
Description: As shown in the Flow Chart of the study, research data were collected from pregnant women who were in the control group at the December intervals with the experimental group. After the completion of the study, this group will also be given an education and training booklet.
Study: NCT05610007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Patients in the prilocaine group were given 50 mg hyperbaric 2% prilocaine (2.5 ml volume) + 25 mcg fentanyl (0.5 ml volume) before undergoing the cystoscopy procedure.
Study: NCT06474845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T-Control® catheter
Description: Patients will be catheterized with T-Control® for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley-type catheter
Description: Patients will be catheterized with a conventional Foley-type catheter for 4 weeks
Study: NCT05460169

Intervention type: DEVICE
Group type: OTHER
Intervention: Renal denervation
Description: The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation
Description: The Paradise® Renal Denervation System (Paradise System) is CE-marked in countries accepting the CE mark. The system is a catheter-based device designed to use ultrasound energy to thermally ablate the afferent and efferent nerves surrounding the renal artery and serving the kidney.
Study: NCT05201495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Description: Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
Study: NCT06527937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DESF
Description: DESF administered in the sublingual space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DESF
Description: DESF administered in the sublingual space.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Injection
Description: Epinephrine manual injection administered intramuscularly according to the approved prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine Injection
Description: Epinephrine manual injection administered intramuscularly according to the approved prescribing information.
Study: NCT06100276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-162
Description: AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-162
Description: AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
Study: NCT06399692

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass grafting (CABG)
Description: Coronary artery bypass grafting (CABG), also called heart bypass surgery, is a medical procedure to improve blood flow to the heart.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart
Study: NCT06435858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10mg
Study: NCT06122662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: Proprietary formulation of sodium phenylbutyrate and taurursodiol
Study: NCT06138795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
Study: NCT06528977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western Diet
Description: Consumption of 10 days of a diet high in added sugars (25% of total caloric intake)
Study: NCT06042998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic radical gastrectomy
Description: Laparoscopic gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic radical gastrectomy
Description: Laparoscopic gastrectomy
Study: NCT05328440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: once a day, 125mg each time, taking for 3 weeks, stopping for 1 week, 4 weeks as a cycle. It is recommended to take medicine at about the same time every day, take it with warm water, and fast at least 1 hour before and after taking medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isethionate Tablets
Description: 400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib Isethionate Tablets
Description: 400mg once a day, oral administration within 30 minutes after breakfast, continuous administration for 28 days as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: the initial dose is 8mg / kg and the subsequent dose is 6mg / kg. It is administered intravenously for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: fluvestrant is administered intravenously on the 1/15 day of the first cycle, and then on the first day of each cycle, 500mg / time, intravenously
Study: NCT06122662

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Comparator
Study: NCT05053308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: IV PCA(fentanyl) Fentanyl bolus = MME \* 15%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Tablet
Description: subligual fentanyl(Narco®) Fentanyl 100mcg/200mcg/300mcg according to the around-the-clock opioid requirement.
Study: NCT06088901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Blood Patch
Description: 2 ml/kg of whole blood (max 100 ml) is obtained via venipuncture. This blood is then injected via the chest tube which will then be clamped for 180 minutes, before being returned to suction. During this period of clamping, the patient will be rotated from side to side intermittently to help the blood move around the extrapleural space.
Study: NCT06435858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06449547

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.